Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health.

BACKGROUND: Glucagon-like-peptide-1 receptor agonists (GLP-1-RA) are increasingly prescribed medications with well-documented gastrointestinal adverse effects. Urologic adverse effects remain poorly characterized. CASE PRESENTATION: A 40-year-old male developed reproducible urinary frequency, penile pruritus, dysuria, pelvic/perineal pain, and sexual dysfunction 3-4 weeks after initiating tirzepatide therapy. Comprehensive infectious evaluation remained negative. Symptoms improved 4 days after discontinuing tirzepatide with complete resolution in 10 days and no recurrence two weeks after last injection. CONCLUSION: This case describes novel urologic adverse effects associated with GLP-1-RA therapy. Clinicians should consider medication-related etiologies in patients with atypical urogenital symptoms with negative infectious workup during GLP-1-RA use.